2 Links and Summaries on New HCV Articles

[Guest guest]

ICAAC: BMS-790052 plus Standard Therapy Cures Most

Genotype 1 Hepatitis C PatientsUp

to 83% of treatment-naive people with difficult-to-treat

genotype 1 hepatitis C virus (HCV) infection achieved

sustained virological response (SVR) with the experimental

HCV NS5A inhibitor BMS-790052 plus pegylated interferon

and ribavirin, according to data presented at the 51st

Interscience Conference on Antimicrobial Agents and Chemotherapy

(ICAAC 2011) this week in Chicago. ICAAC: Didanosine,

Higher HCV Viral Load Predict Liver Fibrosis in HIV/HCV

Coinfected PeopleUse of didanosine (ddI, Videx) -- along

with higher hepatitis C virus (HCV) RNA level, male sex,

and older age -- was a significant risk factor for liver

fibrosis in people with HIV/HCV coinfection, researchers

reported at the 51st Interscience Conference on

Antimicrobial Agents and Chemotherapy (ICAAC 2011) this

week in Chicago.